Commenting on the full year results, Rakesh Kapoor, Chief Executive Officer, said:
"Reckitt Benckiser delivered another strong year, exceeding both our net revenue target (+12%) and adjusted net income target (+10%) in an increasingly tough environment. Like-for-like growth of 4% was underpinned by a robust performance in the base business, especially in Q4.
"Growth was driven in particular by excellent growth in emerging markets, and growth in our Powerbrands - Dettol, Nurofen, Mucinex, Strepsils, Gaviscon and Harpic. SSL had a good first year with LFL growth of 6%, although full year growth is flattered by a soft Q4 last year.
"At the end of 2011, the Suboxone film had captured a 48% volume share of the U.S. market. The in-market sales trend remains on a healthy growth track.
The Board recommends a +8% increase in the final dividend to 70p per share,
bringing the total dividend for 2011 to 125p (+9% versus 2010).
"In 2012 we are targeting total Company net revenue growth, excluding RBP, of 200bps above our market growth rate. We expect the market to grow at 1-2%.
2012 will be a year of higher investment but, ex RBP, we are still targeting to maintain our operating margins. "
